Table 1.
Patient demographics.
| N | Overall | Pre-AJ | Post-AJ | p value | |
|---|---|---|---|---|---|
| Age at breast cancer (years) | 386 | 47.8 ± 8.0 | 47.7 ± 8.3 | 48.0 ± 7.2 | 0.813 |
| Estimated lifetime risk (%) | 386 | 0.001* | |||
| < 30% | 122 (31.6%) | 94 (35.1%) | 28 (23.7%) | ||
| 30–39% | 101 (26.2%) | 76 (28.4%) | 25 (21.2%) | ||
| 40+% | 163 (42.2%) | 98 (36.6%) | 65 (55.1%) | ||
| Risk category | 385 | < 0.001 | |||
| Moderate | 117 (30.4%) | 89 (33.3%) | 28 (23.7%) | ||
| High (non-BRCA) | 163 (42.3%) | 94 (35.2%) | 69 (58.5%) | ||
| BRCA1 | 54 (14.0%) | 43 (16.1%) | 11 (9.3%) | ||
| BRCA2 | 50 (13.0%) | 40 (15.0%) | 10 (8.5%) | ||
| BRCA1 and BRCA2 | 1 (0.3%) | 1 (0.4%) | 0 (0.0%) | ||
| Pathology | 381 | 0.729 | |||
| IDC | 276 (72.4%) | 191 (72.1%) | 85 (73.3%) | ||
| ILC | 30 (7.9%) | 20 (7.5%) | 10 (8.6%) | ||
| Mixed IC | 4 (1.0%) | 4 (1.5%) | 0 (0.0%) | ||
| Pre-Invasive | 71 (18.6%) | 50 (18.9%) | 21 (18.1%) | ||
| Size category | 367 | 0.432 | |||
| Invasive: 0–19 mm | 212 (57.8%) | 152 (60.3%) | 60 (52.2%) | ||
| Invasive: 20+ mm | 92 (25.1%) | 58 (23.0%) | 34 (29.6%) | ||
| In-situ: 0–19 mm | 39 (10.6%) | 25 (9.9%) | 14 (12.2%) | ||
| In-situ: 20 mm | 24 (6.5%) | 17 (6.7%) | 7 (6.1%) | ||
| Grade | 378 | 0.616 | |||
| Grade 1 | 44 (11.6%) | 31 (11.8%) | 13 (11.2%) | ||
| Grade 2 | 119 (31.5%) | 77 (29.4%) | 42 (36.2%) | ||
| Grade 3 | 144 (38.1%) | 104 (39.7%) | 40 (34.5%) | ||
| Carcinoma in-situ | 71 (18.8%) | 50 (19.1%) | 21 (18.1%) | ||
| Lymph node status (pathological) | 323 | 0.038* | |||
| Negative | 239 (74.0%) | 151 (70.2%) | 88 (81.5%) | ||
| 1–3 Nodes Positive | 72 (22.3%) | 56 (26.0%) | 16 (14.8%) | ||
| > 3 Nodes Positive | 12 (3.7%) | 8 (3.7%) | 4 (3.7%) | ||
| TNM stage | 379 | 0.709* | |||
| Stage 0 | 68 (17.9%) | 48 (18.2%) | 20 (17.4%) | ||
| Stage 1 | 188 (49.6%) | 132 (50.0%) | 56 (48.7%) | ||
| Stage 2 | 107 (28.2%) | 73 (27.7%) | 34 (29.6%) | ||
| Stage 3 | 16 (4.2%) | 11 (4.2%) | 5 (4.3%) | ||
| Molecular subtype | 343 | 0.002 | |||
| Luminal A | 238 (69.4%) | 153 (67.7%) | 85 (72.6%) | ||
| Luminal B | 10 (2.9%) | 4 (1.8%) | 6 (5.1%) | ||
| Triple Negative | 89 (25.9%) | 68 (30.1%) | 21 (17.9%) | ||
| HER2 Enriched | 6 (1.7%) | 1 (0.4%) | 5 (4.3%) |
Data are reported as N (column %), with p values from Fisher’s exact tests, or as mean ± SD, with p values from independent samples t-tests, unless stated otherwise. Bold p values are significant at p < 0.05. *p value from Mann–Whitney U test, as the factor is ordinal. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IC invasive carcinoma.